AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
AMG 334 20160172 Pediatric Migraine PK Study.
An Open-label, Randomized, Multiple-dose Study to Evaluate Safety, Tolerability, and
 Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Inclusion Criteria:

 -  Subject's legally acceptable representative has provided informed consent and the
 subject has provided written assent based on local regulations and/or guidelines prior
 to any study-specific activities/procedures being initiated.

 -  Male and female children and adolescents ≥ 6 and <18 years of age upon entry into
 screening

 -  Diagnosis of migraines, with or without aura, according to the International
 Classification of Headache Disorders (ICHD 3rd Edition, 2013) for at least 12 months
 prior to the study screening

 -  Frequency of migraine of ≥ 4 migraine days per month in each of the 3 months prior to
 the study screening period

 Exclusion Criteria:

 -  Currently receiving treatment in another investigational device or drug study

 -  History of migraine with brainstem aura or hemiplegic migraine headache

 -  Medical history or other condition that compromises the ability of the subject or
 legally acceptable representative to give appropriate informed consent and/or assent

 -  Malignancy except non-melanoma skin cancers or cervical cancer in situ within the last
 5 years.

 -  Presence of any clinical condition that in opinion of the investigator might increased
 the risk of subjects participating in the study.